NeuroPace (NPCE)
(Delayed Data from NSDQ)
$7.53 USD
-0.07 (-0.92%)
Updated May 24, 2024 04:00 PM ET
3-Hold of 5 3
D Value C Growth B Momentum C VGM
Price, Consensus and EPS Surprise
NPCE 7.53 -0.07(-0.92%)
Will NPCE be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for NPCE based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for NPCE
Globus Medical (GMED) Q1 Earnings and Revenues Beat Estimates
Thermo Fisher Scientific (TMO) Tops Q1 Earnings and Revenue Estimates
NPCE: What are Zacks experts saying now?
Zacks Private Portfolio Services
RxSight, Inc. (RXST) Reports Q3 Loss, Tops Revenue Estimates
Alphatec (ATEC) Reports Q3 Loss, Tops Revenue Estimates
Accuray (ARAY) Reports Q1 Loss, Misses Revenue Estimates
Other News for NPCE
NeuroPace post Q1 move 'overdone,' says Lake Street
NeuroPace post Q1 move 'overdone,' says Lake Street
NeuroPace to Participate in Two Healthcare Conferences in May
NeuroPace, Inc. (NPCE) Q1 2024 Earnings Call Transcript
NeuroPace’s Strong Q1 Performance and Promising Growth Prospects Affirm Buy Rating